Navigation Links
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
Date:11/13/2013

nd disease.

ADVATE has a demonstrated efficacy profile and a low rate of inhibitor development.  ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives. Because no blood-derived components are added at any stage of the manufacturing process, the potential risk of transmitting pathogens that may be carried in blood-based additives is eliminated. There have been no confirmed reports of transmission of HIV, HBV or HCV with rFVIII treatments.

ADVATE is approved in 60 countries worldwide including the United States, Canada, 27 countries in the European Union, Argentina, Australia, Brazil, Chile, China, Colombia, Croatia, Ecuador, Hong Kong, Iceland, Iraq, Japan, Kuwait, Macau, Malaysia, Mexico, New Zealand, Norway, Panama, Puerto Rico, Serbia, Singapore, South Korea, Suriname, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, Uruguay, and Venezuela.

Detailed Important Risk Information for ADVATE

ADVATE is contraindicated in patients with known anaphylaxis to mouse or hamster protein or other constituents of the product.

Allergic-type hypersensitivity reaction
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. NSF report detailing growth in graduate enrollment in science & engineering in the past decade
2. King Richard III search in new phase after discovery has potential to rewrite history
3. National Geographic unveils new phase of genographic project
4. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
5. In beef production, cow-calf phase contributes most greenhouse gases
6. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
7. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
8. Carnegie Mellon neuroscientists discover new phase of synaptic development
9. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
10. New sickle cell anemia therapy advances to Phase II clinical trials
11. Biozoom Enters Into Commercial Phase of Scanner Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... Sieve elements are a key component of phloem, the ... wide range of signalling molecules. Elongated cylindrical cells are ... arranged end-to-end to form sieve tubes which in turn ... "Sieve elements are very special cells which play ... very little has been known about their differentiation," says ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2A map for eye disease 2Developmental regulation of important plant phloem components discovered 2
... years, researchers have worked to develop a number of ... vaccines are not intended to prevent cancer; rather, they ... Unlike traditional chemotherapy, vaccines have relatively low toxicity and, ... these vaccines have rarely been designed to directly stimulate ...
... physics to show how our circadian clocks manage to ... , In an article appearing March 13 in the ... Federale de Lausanne demonstrate that the stability of cellular ... studies in families affected by advanced sleep phase syndrome. ...
... role in the development of the placenta, the organ that ... fetus during pregnancy, and perhaps in miscarriages. , Those ... gene in mice. In humans, this gene, when mutated, raises ... retinoblastoma. Two decades ago, it was identified as the first ...
Cached Biology News:Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3Keeping the body in sync -- The stability of cellular clocks 2Tumor-suppressor gene is critical for placenta development 2Tumor-suppressor gene is critical for placenta development 3
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... consumers, are increasingly searching for food alternatives that ... nutritional benefits. The food ingredient market has numerous ... players such as Vital Force Technology (VFT). ... more than 4,000 energetic patterns, all tested to ...
(Date:7/31/2014)... British mathematician (1912-1954), is famous for a number of ... In 1936 he published a paper, which laid the ... of a computer algorithm. He next played a pivotal ... which cracked the German military codes, enabling the Allies ... in the late 1940,s he turned his attention to ...
(Date:7/31/2014)... , July 31, 2014 ... Market Research "Quantum Dots Market - Global Industry Analysis, ... the market was valued at USD 88.5 million in ... by 2023, growing at a CAGR of 53.8% from ... Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing ...
(Date:7/31/2014)... Research and Markets has announced ... report to their offering. ... of the genetic material or genomes of an organism. ... the discovery and development of diagnostic and therapeutic solutions ... Genomics is supported by three major product segments: Instruments, ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Inc., a consulting firm,providing outcomes research and health ... announces the addition of,Anthony J. Vita, MD, MPH ... clinical,professionals. The specialized background of these two practitioners ... directly to those clients,seeking to enhance the clinical ...
... Palatin Technologies,Inc. (Amex: PTN ) will announce its ... 2007 before the open of the U.S. financial,markets. ... audio webcast,hosted by Palatin,s executive management team on November ... operations in greater detail and provide,an update on corporate ...
... SOUTH SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. ... for the third quarter,ended September 30, 2007. ... were $26.8 million,compared to $23.5 million for the ... 2006 to 2007 was primarily due to revenue ...
Cached Biology Technology:EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Synthetic peptide derived from an internal region ... target of rapamycin FRAP RAFT1 RAPT1). ... On Western blots it identifies the ... Human (positive control: HEK293 cell lysates). Based ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: